Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

Hospital


Location: London, United Kingdom (GB) GB

ISNI: 0000000404170461

ROR: https://ror.org/034vb5t35

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy (2026) Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, et al. Journal article Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial (2026) Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, et al. Journal article Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation (2026) Wu JH, Bautista F, Brivio E, Willemse M, Kowalski K, Jermain B, Garrett M, et al. Journal article Translating ctDNA into cutaneous melanoma care: An international expert survey (2026) Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, et al. Journal article Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium (2026) Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, et al. Journal article, Review article Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC (2026) Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Journal article Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer (2026) Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, et al. Journal article, Review article Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy (2026) Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, et al. Journal article Towards Clinical Translation of Intravoxel Incoherent Motion MRI: Acquisition and Analysis Consensus Recommendations (2026) Sigmund EE, Rauh SS, Iima M, Federau C, Hernando D, Jalnefjord O, Jansen JF, et al. Journal article